FYI I was not aware of the fact that Sandoz is now totally unrelated to Novartis and in my view this makes the Sandoz /Avecho arrangement more significant.The Sandoz medical cannabis effort here is different to the Novartis effort which involved recreational cannabis[ eg cannabis producer Tilray joins Novartis and the maker of Budweiser beer to develop new marijuana products].
Sandoz is now a standalone company having been spun off from Novartis on October 4, 2023 to focus on generic and biosimilar medicines.[ A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires].
Clearly Sandoz have seen something that they like in the Avecho offering in which the difference in cost between the various components of the approved product are insignificant in relation to the revenue benefits of a successfully approved product and its potential market size. Kens
AVE Price at posting:
0.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)